Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01714089 (ClinicalTrials.gov)	March 2013	19/10/2012	Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis	A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: RNS60 125 ml;Drug: RNS60 250 ml;Drug: Interferon beta 1a	Revalesio Corporation	NULL	Withdrawn	18 Years	50 Years	Both	0	Phase 2	United States
2	NCT00146068 (ClinicalTrials.gov)	September 2004	1/9/2005	EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis	Phase IV Double-Blind Randomized Study to Evaluate Safety and Efficacy of Interferon Beta-1a (Avonex) Plus Simvastatin (Zocor) Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis Over a One Year Period	Multiple Sclerosis	Drug: Avonex /Zocor	University of North Carolina	NULL	Completed	18 Years	60 Years	Both	30	Phase 4	United States
3	NCT00913666 (ClinicalTrials.gov)	November 2002	2/6/2009	Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers	A Pilot Multi-Center, Open-Label, Assessor Blinded, Prospective Profiling Study in MS Subjects Treated With AVONEX®, MS Subjects Naïve to Treatment, and Healthy Control Subjects	Multiple Sclerosis	Drug: Interferon beta -1a (Avonex)	Biogen Idec	NULL	Completed	18 Years	65 Years	Both	121	Phase 4	NULL
4	NCT00915460 (ClinicalTrials.gov)	September 1999	5/6/2009	Open-Label Safety Extension Study of Avonex	An Open-Label Safety Extension Study of AVONEX® (Interferon Beta-1a) Treatment in Subjects Who Completed Biogen Studies C95-812, C96-823, or C97-830	Multiple Sclerosis	Drug: Interferon beta -1a (Avonex)	Biogen Idec	NULL	Completed	N/A	N/A	Both	408	Phase 4	NULL